U.S. Bacterial Conjunctivitis Drugs Market

- Table of Content -

Chapter 1. Preface

    1.1. Report Description

    1.2. Market Segmentation

    1.3. Research Methodology

    1.4. Assumptions

Chapter 2. Executive Summary

    2.1. Market Snapshot: U.S. Bacterial Conjunctivitis Drugs Market

Chapter 3. U.S. Bacterial Conjunctivitis Drugs Market Overview

    3.1. Market Dynamics and Overview

    3.2. Incidence Rate of Bacterial Conjunctivitis in the U.S.

    3.3. Market Drivers

        3.3.1. Rising Incidence of Ophthalmic Bacterial Infection

        3.3.2. Susceptibility Among Various Age Groups Ranging from Neonates to Geriatrics

    3.4. Market Restraints

        3.4.1. Increasing Genericization of Antibacterial Drugs Could Lead to a Crowded and Unprofitable Market

        3.4.2. Upcoming Patent Expirations likely to Hinder Market Growth

        3.4.3. Burgeoning Multi-Drug Resistant Bacterial Strains Expected To Hinder Market Growth

    3.5. Market Opportunities

        3.5.1. Implementation of Product Development Partnerships (PDPs) Business Models

        3.5.2. Focus on Designing and Producing Combination Drug Products

    3.6. Event Impact Assessment: U.S. Bacterial Conjunctivitis Market

    3.7. Regulatory Framework

    3.8. Patents and Patent Challenges: Overview

    3.9. List of API Manufacturers

    3.10. Key Discontinued Products: U.S. Bacterial Conjunctivitis Drugs Market

        3.10.1. Oxytetracycline/Polymyxin B

        3.10.2. Sulfisoxazole Ophthalmic

        3.10.3. Phenylephrine/Sulfacetamide Sodium

        3.10.4. Chloramphenicol

    3.11. Market Attractiveness Analysis: U.S. Bacterial Conjunctivitis Drugs Market, by Drug Type

    3.12. Market Share Analysis: U.S. Bacterial Conjunctivitis Drugs Market, by Key Players, 2013 (Value %)

Chapter 4. U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class

    4.1. Overview

        4.1.1. Recommended Dosages for Treatment of Bacterial Conjunctivitis

        4.1.2. U.S. Bacterial Conjunctivitis Drugs Market Revenue, by Drug Class, 2012 – 2024 (USD Million)

    4.2. Fluoroquinolones

        4.2.1. Fluoroquinolones for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 – 2024 (USD Million)

        4.2.2. Ciprofloxacin

            4.2.2.1. U.S. Ciprofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

        4.2.3. Ofloxacin

            4.2.3.1. U.S. Ofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

        4.2.4. Levofloxacin

            4.2.4.1. U.S. Levofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

        4.2.5. Moxifloxacin

            4.2.5.1. U.S. Moxifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

        4.2.6. Gatifloxacin

            4.2.6.1. U.S. Gatifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

        4.2.7. Besifloxacin

            4.2.7.1. U.S. Besifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

    4.3. Aminoglycosides

        4.3.1. Aminoglycosides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 – 2024 (USD Million)

        4.3.2. Tobramycin

            4.3.2.1. U.S. Tobramycin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

        4.3.3. Gentamycin

            4.3.3.1. U.S. Gentamycin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

    4.4. Macrolides

        4.4.1. Macrolides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 – 2024 (USD Million)

        4.4.2. Erythromycin

            4.4.2.1. U.S. Erythromycin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

        4.4.3. Azithromycin

            4.4.3.1. U.S. Azithromycin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

    4.5. Others (Bacitracin, Doxycycline, Polymyxin, and Fusidic Acid)

        4.5.1. U.S. Others Market Revenue, by Bacterial Conjunctivitis, 2012 – 2024 (USD Million)

Chapter 5. U.S. Bacterial Conjunctivitis Drugs Market, Pipeline Assessment

    5.1. Overview

    5.2. Vancomycin Ophthalmic Ointment

        5.2.1. U.S. Vancomycin Ophthalmic Ointment for Bacterial Conjunctivitis Market Revenue, 2019 – 2024 (USD Million)

    5.3. Early Stage (Phase I and Phase II trials) – Tabular Representation

Chapter 6. Recommendations

Chapter 7. Company Profiles

    7.1. Actavis plc (now Allergan plc)

        7.1.1. Company Overview

        7.1.2. Financial Overview

        7.1.3. Product Portfolio

        7.1.4. Business Strategies

        7.1.5. Recent Developments

    7.2. Akorn, Inc.

        7.2.1. Company Overview

        7.2.2. Financial Overview

        7.2.3. Product Portfolio

        7.2.4. Business Strategies

        7.2.5. Recent Developments

    7.3. Bayer AG

        7.3.1. Company Overview

        7.3.2. Financial Overview

        7.3.3. Product Portfolio

        7.3.4. Business Strategies

        7.3.5. Recent Developments

    7.4. F. Hoffmann-La Roche Ltd.

        7.4.1. Company Overview

        7.4.2. Financial Overview

        7.4.3. Product Portfolio

        7.4.4. Business Strategies

        7.4.5. Recent Developments

    7.5. Merck & Co., Inc.

        7.5.1. Company Overview

        7.5.2. Financial Overview

       7.5.3. Product Portfolio

        7.5.4. Business Strategies

        7.5.5. Recent Developments

    7.6. Novartis AG

        7.6.1. Company Overview

        7.6.2. Financial Overview

        7.6.3. Product Portfolio

        7.6.4. Business Strategies

        7.6.5. Recent Developments

    7.7. Perrigo Company plc

        7.7.1. Company Overview

        7.7.2. Financial Overview

        7.7.3. Product Portfolio

        7.7.4. Business Strategies

        7.7.5. Recent Developments

    7.8. Pfizer, Inc.

        7.8.1. Company Overview

        7.8.2. Financial Overview

        7.8.3. Product Portfolio

        7.8.4. Business Strategies

        7.8.5. Recent Developments

    7.9. Santen Pharmaceutical Co., Ltd.

        7.9.1. Company Overview

        7.9.2. Financial Overview

        7.9.3. Product Portfolio

        7.9.4. Business Strategies

        7.9.5. Recent Developments

    7.10. Valeant Pharmaceuticals International, Inc.

        7.10.1. Company Overview

        7.10.2. Financial Overview

        7.10.3. Product Portfolio

        7.10.4. Business Strategies

        7.10.5. Recent Developments

- List Of Table -

List of Tables

TABLE 1: Market Snapshot: U.S. Bacterial Conjunctivitis Drugs Market

TABLE 2: Upcoming Patents Expiration of Branded Bacterial Conjunctivitis Drugs and Competing Companies of Generic Products

TABLE 3: List of Ciprofloxacin API Manufacturers

TABLE 4: List of Ofloxacin API Manufacturers

TABLE 5: List of Levofloxacin API Manufacturers

TABLE 6: List of Moxifloxacin API Manufacturers

TABLE 7: List of Gatifloxacin API Manufacturers

TABLE 8: List of Besifloxacin API Manufacturers

TABLE 9: List of Tobramycin API Manufacturers

TABLE 10: List of Gentamycin API Manufacturers

TABLE 11: List of Erythromycin API Manufacturers

TABLE 12: List of Azithromycin API Manufacturers

TABLE 13: List of Bacitracin API Manufacturers

TABLE 14: List of Neomycin API Manufacturers

TABLE 15: List of Fusidic Acid API Manufacturers

TABLE 16: Recommended Dosages for Treatment of Bacterial Conjunctivitis

TABLE 17: U.S. Bacterial Conjunctivitis Drugs Market Revenue, by Drug Class, 2012 – 2018 (USD Million)

TABLE 18: U.S. Bacterial Conjunctivitis Drugs Market Revenue, by Drug Class, 2019 – 2024 (USD Million)

TABLE 19: Fluoroquinolones for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 – 2018 (USD Million)

TABLE 20: Fluoroquinolones for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2019 – 2024 (USD Million)

TABLE 21: Aminoglycosides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 – 2018 (USD Million)

TABLE 22: Aminoglycosides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2019 – 2024 (USD Million)

TABLE 23: Macrolides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 – 2018 (USD Million)

TABLE 24: Macrolides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2019 – 2024 (USD Million)

TABLE 25: Early Stage (Phase I and Phase II trials) – Tabular Representation

TABLE 26: Actavis plc: Expenses & Revenue, 2011 – 2013 (USD Million)

TABLE 27: Novartis AG: Expenses & Revenue, 2011 – 2013 (USD Million)

- List Of Chart -

List of Figures

FIG. 1: U.S. Bacterial Conjunctivitis Drugs Market Segmentation

FIG. 2: U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class, 2013 (USD Million)

FIG. 3: U.S. Bacterial Conjunctivitis Drugs Market: Drivers, and Restraints

FIG. 4: Market Attractiveness Analysis: U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class

FIG. 5: Market Share Analysis: U.S. Bacterial Conjunctivitis Drugs Market, by Key Players, 2013 (Value %)

FIG. 6: U.S. Ciprofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

FIG. 7: U.S. Ofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

FIG. 8: U.S. Levofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

FIG. 9: U.S. Moxifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

FIG. 10: U.S. Gatifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

FIG. 11: U.S. Besifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

FIG. 12: U.S. Tobramycin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

FIG. 13: U.S. Gentamycin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

FIG. 14: U.S. Erythromycin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

FIG. 15: U.S. Azithromycin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

FIG. 16: U.S. Others Market Revenue, by Bacterial Conjunctivitis, 2012 – 2024 (USD Million)

FIG. 17: U.S. Vancomycin Ophthalmic Ointment for Bacterial Conjunctivitis Market Revenue, 2019 – 2024 (USD Million)

FIG. 18: Actavis plc.: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 19: Akorn, Inc.: Annual Revenue, 2011 – 2013 (USD million)

FIG. 20: Bayer AG (Bayer HealthCare): Annual Revenue, 2011 – 2013 (USD Million)

FIG. 21: F. Hoffmann-La Roche Ltd.: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 22: Annual Revenue: Merck & Co., Inc., 2011 – 2013 (USD Million)

FIG. 23: Novartis AG: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 24: Perrigo Company plc.: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 25: Pfizer, Inc.: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 26: Santen Pharmaceutical Co., Ltd.: Annual Revenue, 2011 – 2013 (USD million)

FIG. 27: Valeant Pharmaceuticals International, Inc.: Annual Revenue, 2011 – 2013 (USD Million)